FDA issues warning to AcelRx for making false and misleading claims about the risks and benefits of Dsuvia https://www.lawofcompoundingmedications.com/2021/02/fda-issues-warning-to-acelrx-for-making.html As part of the FDA’s ongoing commitment to combat inappropriate opioid use, the agency’s Center for Drug Evaluation and Research has issued a warning letter to AcelRx Pharmaceuticals, Inc. (AcelRx) for the false and misleading promotion of Dsuvia […]
Filed under: General Problems | Leave a Comment »